Cutaneous T-Cell Lymphoma Recurrent Completed Phase 1 Trials for Interleukin-15, human recombinant (DB17467)

Also known as: T-Cell Lymphoma Relapsed / Recurrent T-Cell Lymphoma / Recurrent Cutaneous T-cell lymphoma / T-cell lymphoma recurrent / Relapsed T-Cell Lymphoma / T-cell lymphoma NOS recurrent

IndicationStatusPhase
DBCOND0136063 (Cutaneous T-Cell Lymphoma Recurrent)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02689453Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)Treatment